British HIV Association (BHIVA) guidelines for the treatment of HIV-infected adults with antiretroviral therapy (2006)

HIV Medicine

Volumn 7, Issue 8, 2006, Pages 487-503

  Gazzard, B ^a   Bernard, E J ^b   Boffito, M ^b   Churchill, D ^b   Edwards, S ^b   Fisher, M ^b   Geretti, A M ^b   Johnson, M ^b   Leen, C ^b   Peters, B ^b   Pozniak, A ^b   Ross, J ^b   Walsh, J ^b   Wilkins, E ^b   Youle, M ^b  

^a CHELSEA AND WESTMINSTER HOSPITAL   (United Kingdom)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ABACAVIR; ABACAVIR PLUS LAMIVUDINE; ABACAVIR PLUS LAMIVUDINE PLUS ZIDOVUDINE; AMPRENAVIR; AMPRENAVIR PHOSPHATE; ANTIRETROVIRUS AGENT; ATAZANAVIR; BILIRUBIN; CD4 ANTIGEN; DELAVIRDINE; DIDANOSINE; EFAVIRENZ; EMTRICITABINE PLUS TENOFOVIR DISOPROXIL; ENFUVIRTIDE; INDINAVIR; LAMIVUDINE; LAMIVUDINE PLUS ZIDOVUDINE; LIPID; LOPINAVIR; NELFINAVIR; NEVIRAPINE; PROTON PUMP INHIBITOR; RITONAVIR; SAQUINAVIR; STAVUDINE; TENOFOVIR; UNINDEXED DRUG; VIRUS ANTIBODY; ZALCITABINE; ZIDOVUDINE;

ADULT; ANTIBIOTIC RESISTANCE; ANTIBODY DETECTION; ARTICLE; CARDIOVASCULAR DISEASE; CD4+ T LYMPHOCYTE; CLINICAL TRIAL; COMORBIDITY; DIABETES MELLITUS; DIARRHEA; DISEASE COURSE; DISORIENTATION; DROWSINESS; DRUG COST; DRUG FATALITY; DRUG HALF LIFE; DRUG HYPERSENSITIVITY; DRUG MONITORING; DRUG SUBSTITUTION; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSLIPIDEMIA; DYSPHORIA; GASTROINTESTINAL DISEASE; HEPATITIS; HEPATITIS B; HEPATITIS B VIRUS; HEPATITIS C; HEPATITIS C VIRUS; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERBILIRUBINEMIA; INDIVIDUALIZATION; KIDNEY DYSFUNCTION; LIFESTYLE; LIPOATROPHY; LIVER FAILURE; LYMPHOCYTE COUNT; MEDICAL ASSESSMENT; MEDICAL DECISION MAKING; MEDICAL SOCIETY; MENTAL DISEASE; MOOD DISORDER; MORTALITY; NEURAL TUBE DEFECT; NIGHTMARE; PARANOIA; PATIENT COMPLIANCE; PATIENT EDUCATION; PERIPHERAL NEUROPATHY; PRACTICE GUIDELINE; PRIORITY JOURNAL; PROBLEM SOLVING; RASH; RISK ASSESSMENT; SEPTICEMIA; SLEEP DISORDER; STAPHYLOCOCCUS AUREUS; STEVENS JOHNSON SYNDROME; SUICIDAL IDEATION; TERATOGENICITY; TREATMENT FAILURE; TREATMENT OUTCOME; UNITED KINGDOM; VIRUS LOAD; VIVID DREAM;

ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; DISEASE PROGRESSION; DRUG RESISTANCE, VIRAL; FEMALE; GREAT BRITAIN; HIV INFECTIONS; HIV PROTEASE INHIBITORS; HUMANS; INTEGRASE INHIBITORS; MALE; PATIENT COMPLIANCE; PYRIDAZINES; RECEPTORS, CCR5; REVERSE TRANSCRIPTASE INHIBITORS; RISK ASSESSMENT; SULFONAMIDES;

EID: 33750999624     PISSN: 14642662     EISSN: 14681293     Source Type: Journal    
DOI: 10.1111/j.1468-1293.2006.00424.x     Document Type: Article

References (88)

1. Levy RW, Rayner CR, Fairley CK et al. Multidisciplinary HIV adherence intervention: A randomized study. AIDS Patient Care STDs 2004; 18: 728-735.
2. Rathbun RC, Farmer KC, Stephens JR, Lockhart SM. Impact of an adherence clinic on behavioral outcomes and virologic response in treatment of HIV infection: A prospective, randomized, controlled pilot study. Clin Ther 2005; 27: 199-209.
3. Remien RH, Stirratt MJ, Dolezal C et al. Couple-focused support to improve HIV medication adherence: A randomized controlled trial. AIDS 2005; 19: 807-814.
4. Gallant JE, DeJesus E, Arribas JR et al. for the Study 934 Group. Tenofovir DF, emtricitabine, and efavirenz vs. zidovudine, lamivudine, and efavirenz for HIV. N Engl J Med 2006; 354: 251-260.
5. Schackman BR, Finkelstein R, Neukermans CP, Lewis L, Eldred L. The cost of HIV medication adherence support interventions: Results of a cross-site evaluation. AIDS Care 2005; 17: 927-937.
6. MRC Clinical Trial Units. http://www.ctu.mrc.ac.uk/studies/spartac.asp
7. Philips A for the CASCADE Collaboration. Short-term risk of AIDS according to current CD4 cell count and viral load in antiretroviral drug-naive individuals and those treated in the monotherapy era. AIDS 2004; 18: 51-58.
8. Bayer R, Fairchild AL. Changing the paradigm for HIV testing - the end of exceptionalism. N Engl J Med 2006 355: 647-649.
9. 6. AIDS 2002 16: 1371-1381.
10. Pallela JF, Delona-Knoll M, Cmiel JS et al. Survival benefit of initiating antiretroviral therapy in HIV-infected persons in different CD4 + cell strata. Ann Intern Med 2003; 138: 320-326.
11. Sterne J, May M, Costagliola D et al. Estimating the optimum CD4 threshold for starting HAART in ART-naïve HIV-infected individuals. 13th Conference on Retroviruses and Opportunistic Infections, Denver, CO, February 2006 [Abstract 525].
12. Phillips AN, Dunn DT, Sabin C et al. for the UK collaborative Group on HIV Drug Resistance and the UK CHIC Study Group. Long term probability of detection of HIV-1 drug resistance after starting antiretroviral therapy in routine clinical practice. AIDS 2005; 19: 487-494.
13. Harrigan PR, Hogg RS, Dong WW et al. Predictions of HIV drug-resistance mutations in a large antiretroviral-naive cohort initiating triple antiretroviral therapy. J Infect Dis 2005; 191: 339-347.
14. El-Sadr W, Neaton J. Episodic CD4-guided use of ART is inferior to continuous therapy: Results of the SMART Study. 13th Conference on Retroviruses and Opportunistic Infections, Denver, CO, February 2006 [Abstract 106LB].
15. Gallant JE, DeJesus E, Arribas JR et al. for the Study 934 Group. Tenofovir DF emtricitabine, and efavirenz vs. zidovudine, lamivudine, and efavirenz for HIV. N Engl J Med 2006; 354: 251-260.
16. Montaner JS, Sang MS, Barylski C et al. FOCUS Study: Saquinavir qd regimen versus efavirenz qd regimen 48 week analysis in HIV infected patients. 42nd Interscience Conference on Antimicrobial Agents and Chemotherapy. San Diego, CA, September 2002 [Abstract H-167].
17. Shafer RW, Smeaton LM, Robbins GK et al. Comparison of four-drug regimens and pairs of sequential three-drug regimens as initial therapy for HIV-1 infection. N Engl J Med 2003; 349: 2304-2315.
18. Bartlett JA, Johnson J, Herrera G et al. Long-term results of initial therapy with abacavir and lamivudine combined with efavirenz, amprenavir/ ritonavir or stavudine. J Acquir Immune Defic Syndr 2006; 43: E-pub ahead.
19. Riddler SA, Haubrich R, DiRienzo G et al. A prospective, randomized, phase III trial of NRTI-, PI-, and NNRTI-sparing regimens for initial treatment of HIV-1 infection: ACTG 5142. XVI International AIDS Conference. Toronto, Canada, August 2006. [Abstract THLB0204].
20. Eron J, Yeni P, Gathe J et al. The KLEAN study of fosamprenavir-ritonavir versus lopinavir-ritonavir, each in combination with abacavir-lamivudine, for initial treatment of HIV infection over 48 weeks: A randomised non-inferiority trial. Lancet 2006; 368: 476-482.
21. Staszewski S, Morales JM, Tashima KT et al. Efavirenz plus zidovudine and lamivudine, efavirenz plus indinavir, and indinavir plus zidovudine and lamivudine in the treatment of HIV-1 infection in adults. N Engl J Med 1999; 341: 1865-1873.
22. Gallant JE, Staszewski S, Pozniak A et al. Efficacy and safety of tenofovir DF vs. stavudine in combination therapy in antiretroviral-naive patients. A 3-year randomized trial. J Am Med Assoc 2004; 292: 191-201.
23. van Leth F, Phanuphak P, Ruxrungtham K et al. Comparison of first-line antiretroviral therapy with regimens including nevirapine, efavirenz, or both drugs, plus stavudine and lamivudine: A randomised open-label trial, the 2NN Study. Lancet 2004; 363: 1253-1263.
24. van Leth F, Andrews S, Grinsztejn B et al. The effect of baseline CD4 cell count and HIV-1 viral load on the efficacy and safety of nevirapine or efavirenz-based first-line HAART. AIDS 2005; 19: 463-471.
25. Boly L, Cafaro V, Dyner T. Depressive symptoms predict increased incidence of neuropsychiatric side-effects in patients treated with efavirenz. J Acquir Immune Defic Syndr 2006; 42: 514-515.
26. Important change in SUSTIVA (efavirenz) package insert: Change from pregnancy category C to D. Bristol-Myers Squibb Company, March 2005.
27. Montaner JS, Cahn P, Zala C et al. Randomized, controlled study of the effects of a short course of prednisone on the incidence of rash associated with nevirapine in patients infected with HIV-1. J Acquir Immune Defic Syndr 2003; 33: 41-46.
28. Squires K, Lazzarin A, Gatell JM. Comparison of once-daily atazanavir with efavirenz, each in combination with fixed-dose zidovudine and lamivudine, as initial therapy for patients infected with HIV. J Acquir Immune Defic Syndr 2004; 36: 1011-1019.
29. Staszewski S, Keiser P, Montaner J et al. Abacavir-lamivudine-zidovudine vs indinavir-lamivudine-zidovudine in antiretroviral-naive HIV-infected adults: A randomized equivalence trial. J Am Med Assoc 2001; 285: 1155-1163.
30. Walmsely S, Bernstein B, King M et al. M98-863 Study Team. Lopinavir-ritonavir versus nelfinavir for the initial treatment of HIV infection. N Engl J Med 2002; 346: 2039-2046.
31. Gathe JC Jr, Ive P, Wood R et al. SOLO: 48-week efficacy and safety comparison of once daily fosamprenavir/ritonavir versus twice-daily nelfinavir in naïve HIV-1-infected patients. AIDS 2004; 18: 1529-1537.
32. Dragsted U, Gerstoft J, Pedersen C et al. Randomized trial to evaluate indinavir/ritonavir versus saquinavir/ritonavir in human immunodeficiency type-1 infected patients: The MaxCMin1 trial. J Infect Dis 2003; 188: 634-642.
33. Dragsted UB, Gerstoft J, Youle M et al. A randomized trial to evaluate lopinavir/ritonavir versus saquinavir/ritonavir in HIV-1-infected patients: The MaxCmin2 trial. Antivir Ther 2005; 10: 735-743.
34. Murphy RL, Sanne I, Cahn P et al. Dose ranging, randomized, clinical trial of atazanavir with lamivudine and stavudine in antiretroviral naïve subjects: 48 week results. AIDS 2003; 17: 2603-2614.
35. Sanne I, Piliero P, Squires K et al. Results of a phase 2 clinical trial at 48 weeks (AI424-067): A dose-ranging, safety, and efficacy comparative trial of atazanavir at three doses in combination with didanosine and stavudine in antiretroviral naïve subjects. J Acquir Immune Defic Syndr 2003; 32: 18-29.
36. Squires K, Lazzarin A, Gatell JM et al. Comparison of once-daily atazanavir with efavirenz, each in combination with fixed-dose zidovudine and lamivudine, as initial therapy for patients infected with HIV. J Acquir Immune Defic Syndr 2004; 36: 1011-1019.
37. Malan N, Krantz E, David N et al. Efficacy and safety of atazanavir-based therapy in antiretroviral naive HIV-1 infected subjects, both with and without ritonavir: 48-week results from AI424-089. 13th Conference on Retroviruses and Opportunistic Infections. Denver, CO, February 2006 [Abstract 107LB].
38. Gallant JR, Rodriguez AE, Weinberg WG et al. ESS30009 study. Early virologic nonresponse to tenofovir, abacavir and lamivudine in HIV-infected antiretroviral-naïve subjects. J Infect Dis 2005; 192: 1921-1930.
39. Jemsek J, Hutcherson P, Harper E. Poor virological responses and early emergence of resistance in treatment naïve, HIV-infected patients receiving a once daily triple nucleoside regimen of didanosine, lamivudine, and tenofovir DF. 11th Conference on Retroviruses and Opportunistic Infections, San Francisco, CA, 2004 [Abstract 51].
40. Curtis H, Sabin CA, Johnson MA. Findings from the first national clinical audit of treatment for people with HIV. HIV Med 2003; 4: 11-17.
41. DeJesus E, Herrera G, Teofilo E et al. Abacavir versus zidovudine combined with lamivudine and efavirenz, for the treatment of antiretroviral-naïve HIV-infected adults. Clin Infect Dis 2004; 39: 1038-1046.
42. Gallant JE, Pozniak AL, DeJesus E et al. Efficacy and safety of tenofovir DF (TDF), emtricitabine (FTC) and efavirenz (EFV) compared to fixed dose zidovudine/lamivudine (CBV) and EFV through 96 weeks in antiretroviral treatment-naive patients. XVI International AIDS Conference. Toronto, Canada, August 2006. [Abstract TUPE0064].
43. Moyle G, DeJesus E, Cahn P et al. Abacavir once or twice daily combined with once-daily lamivudine and efavirenz for the treatment of antiretroviral-naive HIV-infected adults: Results of the ziagen once daily in antiretroviral combination Study. J Acquir Immune Defic Syndr 2005; 38: 417-425.
44. Sosa N, Hill-Zabala C, DeJesus E et al. Abacavir and lamivudine fixed dose combination once daily compared with abacavir and lamivudine twice daily in HIV infected patients over 48 weeks. J Acquir Immune Defic Syndr 2005; 40: 422-427.
45. Jones R, Stebbing J, Nelson M et al. Renal dysfunction with tenofovir disoproxil fumarate-containing highly active antiretroviral is not observed more frequently: A cohort and case-controlled study. J Acquir Immune Defic Syndr 2004; 37: 1489-1495.
46. Nelson M, Cooper D, Schooley R et al. The safety of tenofovir DF for the treatment of HIV infection: The first 4 years. 13th Conference on Retroviruses and Opportunistic Infections. Denver, CO, February 2006 [Abstract 781].
47. Moreno S, Domingo P, Palacios R et al. Renal safety of tenofovir disoproxil fumarate in HIV-1 treatment-experienced patients with adverse events related to prior NRTI use: Data from a prospective, observational, multicentre study. J Acquir Immune Defic Syndr 2006; 42: 384-385.
48. Gallant JE, Parish MA, Keruly JC et al. Changes in renal function associated with tenofovir disoproxil fumarate, compared with nucleoside reverse transcriptase inhibitor treatment. Clin Infect Dis 2005; 40: 1194-1198.
49. Winston A, Amin J, Mallon P et al. Minor changes in calculated creatinine clearance and anion gap are associated with tenofovir disoproxil fumarate-containing highly active antiretroviral therapy. HIV Med 2006; 7: 105-111.
50. Johnson MA, Gathe JC Jr, Podzamczer D et al. A once-daily lopinavir/ ritonavir-based regimen provides noninferior antiviral activity compared with a twice-daily regimen. J Acquir Immune Defic Syndr 2006; 43: 153-160.
51. Rauch A, Nolan D, Martin A, McKinnon E, Almeida C, Mallal S. Prospective genetic screening decreases the incidence of abacavir hypersensitivity reaction in the Western Australian HIV cohort study. Clin Infect Dis 2006; 43: 99-102.
52. Reeves I, Churchill D, Fisher M. Clinical Utility of HLA-B*5701 testing in a UK clinic cohort. 12th Annual BHIVA Conference, Brighton, UK, March 2006 [Abstract 019].
53. Podzamcer D, Ferrer E, Sánchez P et al. A randomized comparison of abacavir and stavudine, combined with lamivudine/efavirenz, in antiretroviral-naive patients. Final 96-week results (ABCDE study). 12th Conference on Retroviruses and Opportunistic Infections. Boston, MA, February 2005 [Abstract 587].
54. Maitland D, Moyle G, Hand J et al. Early virologic failure in HIV-1 infected subjects on didanosine/tenofovir/efavirenz: 12-week results from a randomized trial. AIDS 2005; 19: 1183-1188.
55. Saag MS, Cahn P, Raffi F et al. Efficacy and safety of emtricitabine vs. stavudine in combination therapy in antiretroviral-naive patients. A randomized trial. J Am Med Assoc 2004; 292: 180-190.
56. Toro, Hicks C and the RESIST-1 Team. RESIST-1: A phase 3 randomized, controlled, open-label multicenter trial comparing tipranavir/ritonavir (TPV/r) to an optimized comparator protease inhibitor/r (CPI/r) regimen in antiretroviral (ARV) experienced patients: 24-week data. 44th Interscience Conference on Antimicrobial Agents and Chemotherapy. Washington DC, October-November 2004 [Abstract H-1137a].
57. Cahn P and the RESIST 2 Team. 24 week data from RESIST 2: Phase 3 study of the efficacy and safety of either tipranavir/ritonavir or an optimized ritonavir-boosted standard of care comparator PI in a large randomized multicenter trial in treatment-experienced HIV+patients. 7th International Congress on Drug Therapy in HIV Infection. Glasgow, UK, November 2004 [Abstract PL14.3].
58. Katlama C, Carvalho MI, Cooper D et al. TMC 114/r out performs investigator selected PI(s) in three class-experienced patients: Week 24 primary analysis of POWER 1 (TMC 114-C213). 3rd IAS Conference on HIV Pathogenesis and Treatment. Rio de Janeiro, Brazil, July 2005 [Abstract WeOaLB0102].
59. Thommes JA, Demasi R, Haubrich R. Improved virologic response in three-class experienced patients when an active boosted protease inhibitor is used with enfuvirtide (ENF). 43rd Annual Infectious Disease Society of America. San Francisco, CA, September 2005 [Abstract 785].
60. Hill A, Moyle G. Relative antiviral efficacy of TMC114/r and tipranavir/ r versus control PI in the POWER and RESIST trials. 12th Annual Conference of the British HIV Association. Brighton, UK, March 2006 [Abstract P1].
61. Murray JS, Elashoff MR, Iacono-Connors LC et al. The use of plasma HIV RNA as a study endpoint in efficacy trials of antiretroviral drugs. AIDS 1999; 13: 797-804.
62. Miller V, Sabin C, Hertogs K et al. Virological and immunological effects of treatment interruptions in HIV-1 infected patients with treatment failure. AIDS 2000; 14: 2857-2867.
63. Ledergerber V, Lundgren JD, Walker AS et al. of trend in CD4-positive T-cell count and mortality among HIV-1-infected individuals with virological failure to all three antiretroviral-drug classes. Lancet 2004; 364: 51-62.
64. Raffanti SP, Fusco JS, Sherrill BH et al. Effect of persistent moderate viremia on disease progression during HIV therapy. J Acquir Immune Defic Syndr 2004; 37: 1147-1154.
65. Solomon A, Lane N, Wightman F, Gorry PR, Lewin SR. Enhanced replicative capacity and pathogenicity of HIV-1 isolated from individuals infected with drug-resistant virus and declining CD4+T-cell counts. J Acquir Immune Defic Syndr 2005; 40: 140-148.
66. Kristiansen TB, Pedersen AG, Eugen-Olsen J, Katzenstein TL, Lundgren JD. Genetic evolution of HIV in patients remaining on a stable HAART regimen despite insufficient viral suppression. Scand J Infect Dis 2005; 37: 890-901.
67. Hatano H, Hunt P, Weidler J et al. Rate of viral evolution and risk of losing future drug options in heavily pre-treated patients remaining on stable partially suppressive regimen. 13th Conference on Retroviruses and Opportunistic Infections. Denver, CO, February 2006 [Abstract 615].
68. Machouf N, Thomas R, Nguyen VK et al. Effects of drug resistance on viral load in patients failing antiretroviral therapy. J Med Virol 2006; 78: 608-613.
69. Nijhuis M, Schuurman R, de Jong D et al. Increased fitness of drug resistant HIV-1 protease as a result of acquisition of compensatory mutations during suboptimal therapy. AIDS 1999; 13: 2349-2359.
70. Palmer S, Kearney M, Maldarelli F. Multiple, linked human immunodeficiency virus type 1 drug resistance mutations in treatment-experienced patients are missed by standard genotype analysis. J Clin Microbiol 2005; 43: 406-413.
71. Deeks SG, Wrin T, Liegler T et al. Virologic and immunologic consequences of discontinuing combination antiretroviral-drug therapy in HIV patients with detectable viremia. N Engl J Med 2001; 344: 472-480.
72. Lawrence J, Huppler Hullsiek K, Thackeray L et al. Final results of CPCRA 064: A randomized trial examining structured treatment interruption for patients failing therapy with multi-drug resistant HIV. 12th Conference on Retroviruses and Opportunistic Infections. Boston, MA, February 2005 [Abstract 579].
73. Walmsley S, LaPierre N, Loutfy M et al. CTN 164: A prospective randomized trial of structured treatment interruption vs immediate switching in HIV-infected patients experiencing virologic failure on HAART. 12th Conference on Retroviruses and Opportunistic Infections. Boston, MA, February 2005 [Abstract 580].
74. Beatty G, Lu J, Hunt P et al. Randomized pilot study of immediate enfuvirtide-based therapy vs a treatment interruption followed by enfuvirtide-based therapy in highly treatment-experienced patients. Abstracts of the 12th Conference on Retroviruses and Opportunistic Infections. Boston, MA, February 2005 [Abstract 581].
75. Deeks SG, Hoh R, Neilands TB et al. Interruption of treatment with individual therapeutic drug classes in adults with multidrug-resistant HIV-1 infection. J Infect Dis 2005; 192: 1537-1544.
76. Dragsted U, Fox Z, Mathiesen L et al. for the COLATE Trial Group. Final week 48 analysis of a phase 4, randomised, open-label, multi-center trial to evaluate safety and efficacy of continued lamivudine twice daily versus discontinuation of lamivudine in HIV-1-infected adults with virological failure on ongoing combination treatments containing lamivudine: The COLATE Trial. 11th Conference on Retroviruses and Opportunistic Infections. San Francisco, CA, February 2004 [Abstract 549].
77. Eron JJ Jr, Bartlett JA, Santana JL et al. Persistent antiretroviral activity of nucleoside analogues after prolonged zidovudine and lamivudine therapy as demonstrated by rapid loss of activity after discontinuation. J Acquir Immune Defic Syndr 2004; 37: 1581-1583.
78. Campbell TB, Shulman NS, Johnson SC et al. Antiviral activity of lamivudine in salvage therapy for multidrug-resistant HIV-1 infection. Clin Infect Dis 2005; 41: 236-242.
79. Castagna A, Danise A, Menzo S et al. Lamivudine monotherapy in HIV-1-infected patients harbouring a lamivudine-resistant virus: A randomized pilot study (E-184V study). AIDS 2006; 20: 795-803.
80. Wensing AMJ et al. First representative prospective surveillance data on HIV baseline drug resistance from 17 countries in Europe; the SPREAD-programme. 4th European HIV Drug Resistance Workshop. Monte Carlo, Monaco, March 2006 [Abstract 1].
81. Cane P, Chrystie I, Dunn D et al. Time trends in primary resistance to HIV drugs in the United Kingdom: Multicentre observational study. Br Med J 2005; 331: 1368-1372.
82. Garcia-Diaz A, Booth C, Nebbia G, Chawla A, Johnson M, Geretti AM. Transmitted drug resistance clusters with the infecting HIV-1 subtype: A single centre analysis of all new HIV-1 diagnoses in London. XV International Drug Resistance Workshop. Sitges, Spain, June 2006 [Abstract 113].
83. Costagliola D, Descamps D, Assoumou L et al. and the ANRS AC11 Resistance Study Group. Prevalence of resistance to at least one drug in treated HIV infected patients with viral load >1,000copies/mL in 2004: A French nationwide study. 4th European HIV Drug Resistance Workshop. Monte Carlo, Monaco, March 2006 [Abstract 6].
84. Castagna A, Danise A, Menzo S et al. Lamivudine monotherapy in HIV-1-infected patients harbouring a lamivudine-resistant virus: A randomized pilot study (E-184V study). AIDS 2006; 20: 795-803.
85. Stone C, Holbrook J, Madsen H, Modha S, Craig C. Amplification and sequencing of HIV-1 from low viral load plasma samples and analysis and interpretation of sequences obtained. 4th European HIV Drug Resistance Workshop. Monte Carlo, Monaco, March 2006 [Abstract 63].
86. Johnson JA, Li J-F, Wei X et al. Baseline detection of low-frequency drug resistance-associated mutations is strongly associated with virological failure in previously antiretroviral-naïve HIV-1-infected persons. XV International HIV Drug Resistance Workshop. Sitges, Spain, July 2006 [Abstract 46].
87. Geretti AM. HIV-1 subtypes: Epidemiology and significance for HIV management. Curr Opin Infect Dis 2006; 19: 1-7.
88. Lazzarin A, Queiroz-Telles F, Frank I et al. TMC114 provides durable viral load suppression in treatment-experienced patients: POWER 1 and 2 combined week 48 analysis. XVI International AIDS Conference, Toronto, Canada, August 2006 [Abstract TUAB0104].